Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail
-

FDA Drug Safety Newsletter - Volume 1, Number 1, Fall 2007

This publication provides postmarketing information to healthcare professionals to enhance communication of new drug safety information, raise awareness of reported adverse events, and stimulate additional adverse event reporting.
In This Issue
 

Welcome from the Commissioner

Editor's Note

Postmarketing Reviews

New Molecular Entity (NME) - Early Safety Findings

Drug Safety Communications

  doctor holding baby, test tubes, pills coming out of a vial

U.S. Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
5600 Fishers Lane, Rockville MD 20857-0001
Phone: 1-888-INFO-FDA (1-888-463-6332)

Renan A. Bonnel, Pharm.D., M.P.H
Senior Scientific Editor

Acknowledgments:
Office of Surveillance and Epidemiology and Office of New Drugs

Contributing Author:
Jennie Chang, Pharm.D. (Rituximab, Temozolomide)

We value your comments. Please let us know by reaching us at Comments.  All text in the Drug Safety Newsletter is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.
-
-